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Abstract
Objective: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type
(wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC).
Methods: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC in eight hospitals in
the Netherlands between 2009 and 2012 were included in our real-world study. Outcome measures were costs per
life-year (LY) and costs per quality-adjusted LY (QALY) gained. A Markov model was developed, and a time horizon
of four years was applied. Outcomes were calculated from Kaplan-Meier survival curves from patient-level data and
literature. Direct medical costs were estimated in all centers (2013 values), and incremental cost-effectiveness ratios
(ICERs) were calculated. Results were discounted, and a probabilistic sensitivity analysis was performed.
Results: Administration of cetuximab in third-line treatment of mCRC resulted in a gain of 0.29 LYs and 0.25 QALYs
compared with BSC. In the four-year study period, average discounted healthcare costs were €36,637 in the
cetuximab group vs. €3648 in the BSC group. The discounted ICERs of cetuximab vs. BSC in the real-world setting
were €114,907and €133,527 per LY and QALY gained, respectively.
Conclusions: Results of this cost-effectiveness analysis showed that third-line treatment with cetuximab for patients
with KRAS (exon 2) wt mCRC offered clinical benefits at additional cost. The real-world ICERs were in line with those
of previously published cetuximab and panitumumab cost-utility models.
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Background
Cancer is the most frequent cause of mortality world-
wide, with an estimated 8.2 million cancer-related deaths
in 2012. Colorectal cancer (CRC) is one of the most
prevalent cancers, the third most commonly diagnosed
cancer in men and the second in women, with 746,000
and 614,000 new cases annually, respectively. Addition-
ally, it is the third-leading cause of cancer-related mor-
tality worldwide, with 373,500 deaths annually [1].
The incidence of CRC is expected to increase in the com-
ing decades. Therapies containing oxaliplatin, irinotecan,
and biologics have improved overall survival (OS). In the
mid-1970s, 5-year OS rates were 50%, and this rate has
since increased to 66% [2]. Biologic agents targeting vascu-
lar endothelial growth factor, its receptor, or epider-
mal growth factor receptor (EGFR) are the mainstay of
biologic treatment options.
Two drugs targeting EGFR have been licensed, cetuxi-
mab and panitumumab [3, 4]. For these drugs, reim-
bursement within the Dutch healthcare system was
regulated under an “expensive drugs policy.” This policy
allowed for conditional reimbursement, contingent on
delivering evidence of real-world drug utilization and
demonstrating associated cost-effectiveness in Dutch
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daily practice after 4 yrs. In this paper we present the re-
sults of a real-world study concerning cost-effectiveness
of cetuximab in third-line treatment of patients with
KRAS (exon 2) wild-type (wt) metastatic CRC (mCRC)
compared with best supportive care (BSC).
Methods
Design
We performed a retrospective observational study of
patients with KRAS (exon 2) wt mCRC who received
cetuximab or BSC between 2009 and 2012 in eight hos-
pitals in the Netherlands. The participating medical
centers were academic and general hospitals located in
the central and western parts of the Netherlands.
Approval for the study was obtained from medical
ethics committees and the board of directors where
medical ethical review was not required.
Patients were eligible for this study if they had been
diagnosed with mCRC, experienced treatment failure
with two prior lines of anticancer drug therapy, had
been tested for KRAS (exon 2) mutation, and had re-
ceived cetuximab monotherapy or BSC. Information
on all patients who were tested for KRAS status was
obtained from each hospital, irrespective of what
treatment they had received. All patients diagnosed
with mCRC were included in the study. Patients diag-
nosed with KRAS wt mCRC and treated with cetuxi-
mab were identified through the hospital pharmacy.
Their patient data were grouped into either a treated
group, which included all patients treated with cetuxi-
mab, or a control group consisting of patients tested
for a KRAS (exon 2) status but who had not subse-
quently received cetuximab. The inclusion date for
this study was the date that KRAS (exon 2) status
was confirmed. Clinical data were collected from the
date on which the KRAS (exon 2) status test had
been ordered. Patients were followed up until either
death or the end of data collection, in June 2013.
No direct comparison could be made between pa-
tient groups receiving either cetuximab or BSC, due
to differences in baseline characteristics, including
KRAS (exon 2) status. This was considered in a
matching protocol. Two sub-analyses were performed
to correct for possible differences. Firstly, only pa-
tients who were treated in the third line were com-
pared. Secondly, pairs were created matched on nine
variables: gender, age, presence and severity of comor-
bidities, location of primary tumor, number of organs
with metastasis, KRAS (exon 2) mutation status, and
number and length of prior treatments. Age was
matched using a difference calculation. If the differ-
ence between the age of the cetuximab-treated patient
and the BSC-treated patient was 5 yrs or less, this
was considered a match. A similar strategy was used
for length of treatment; a difference in treatment dur-
ation of 30 days or less was considered a match.
Performance status and laboratory test results were
not included in the matching technique due to the
large amount of missing information. However, the
presence of comorbidity, the Charlson Comorbidity
Index, and the number of organs with metastases
were considered an adequate proxy for these vari-
ables. A patient who was treated with cetuximab had
to match a patient treated with BSC on these three
criteria as well as four of the remaining six criteria to
be considered a match. No matching control could be
found for three cetuximab-treated patients, and they
were thus excluded from the analysis. When multiple
matching cases could be identified, the first matching
(previously unmatched) BSC-treated patient available
was chosen as a control.
Data on disease progression could not be obtained
from hospital records for patients receiving BSC as these
data are not routinely collected when no anticancer ther-
apy is administered. Outcomes from Karapetis et al. [5]
were used to estimate effectiveness of BSC in daily prac-
tice because this study compared third-line cetuximab
plus BSC vs. BSC alone. By combining the extrapolated
hazard ratio from the real-world cetuximab group with
the hazard ratio from Karapetis et al., we calculated the
hazard ratio of the real-world BSC group. This provided
an effect estimate for the time from treatment start to
disease progression. Although clinical trial patients may
have more favorable baseline characteristics than a
real-world population, we assumed that the effect ratio
would be similar. Overall survival (OS) curves were
drawn using the Kaplan-Meier method. Statistical sig-
nificance was assumed if the p value was below 0.05.
Outcome measures were costs per life-year (LY) gained
and costs per quality-adjusted LY (QALY) gained.
Data collection
Data were collected from case report forms for 287
patients. Patient characteristics included age, gender,
Eastern Cooperative Oncology Group performance sta-
tus, laboratory values (e.g., hemoglobin, liver and kidney
panels, and carcinoembryonic antigen), KRAS (exon 2)
status, and the test used to determine mutation status.
Information on OS was available for all patients, while
progression-free survival (PFS) data were available only
for those patients treated with cetuximab. If a patient
had died, the date of death was recorded; if disease had
progressed, the date of the diagnostic test (e.g., blood
work and radiological test) was recorded. Data on drug
utilization were collected, including details regarding
cetuximab administration, such as planned dose and
actual dose administered. For reported adverse events,
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grade, duration, and drug management measures were
recorded. Furthermore, for cost analysis, resource use
data, such as hospital days, outpatient visits, laboratory
tests, medical procedures, and other drugs, were col-
lected for both patient groups.
Unit costs for the various types of resources used were
expressed in 2013 euros and were taken from a previous
cost-effectiveness study in mCRC and inflated to reflect
2013 costs [6]. When unit costs were not available, they
were derived from the Dutch Manual for Costing, the Dutch
Healthcare Authority, or the literature (Table 1) [7, 8].
Model structure
A Markov model was developed to simulate patient tran-
sition through three distinct health states: mCRC before
disease progression, progressive disease, and death (Fig. 1).
All patients started in the progression-free health state
(“mCRC before disease progression”) and could transition
to either “progressive disease” or “death.” From “progres-
sive disease,” patients could transition only to “death.”
Cycle length was defined as 2 weeks because cetuximab is
given weekly [6, 9, 10].
Costs and effects were discounted at 4% and 1.5%, re-
spectively, in accordance with Dutch guidelines [11]. The
time horizon for the base-case analysis was set as 4 yrs to
allow all effects and costs to accumulate. This was consid-
ered adequate to represent a lifetime horizon because me-
dian OS times of 8.1 and 9.5 months have been reported
with cetuximab in the third-line treatment of KRAS (exon
2) wt mCRC [5].
Sensitivity analysis
To reflect the uncertainty regarding the parameters and
observed variables used in the model, a probabilistic sen-
sitivity analysis (PSA) was performed. A PSA quantifies
model outcomes assuming parameter values are point
estimates from a probability distribution. In a PSA, for
each variable, a point estimate is drawn from its respect-
ive distribution, providing insight into the uncertainty
surrounding parameter values (Table 2).
Results
Comparison of baseline characteristics
Baseline characteristics for age, performance status, and
duration of treatment show statistically significant differ-
ences between groups (Table 3). Patients receiving
cetuximab had a better performance status than patients
receiving BSC. The total duration of treatment was sig-
nificantly longer for cetuximab patients. The duration of
active treatment prior to start of cetuximab or BSC did
not differ between groups. The differences between the
two groups, especially regarding performance status,
suggest that any comparison between the two groups
must be interpreted with caution.
Base-case analysis
Based on Kaplan-Meier estimates for patients in the
third line of treatment, the median OS was 5.2 months
and 2.5 months in the cetuximab and BSC groups, re-
spectively (p < 0.05) (Fig. 2). The results of the base case
are shown in Table 4. The mean survival of patients
treated with cetuximab was 0.61 LYs (7.32 months) com-
pared with 0.32 LYs (3.84 months) in the BSC group,
resulting in survival gains favoring the cetuximab group
of 0.29 LYs (approximately 3 months). The
quality-adjusted result for the cetuximab group was 0.48
QALYs. The result for the BSC group was 0.24 QALYs, a
gain of 0.25 QALYs (after rounding). The discounted ef-
fects were nearly identical.
For patients treated with cetuximab, the average total
costs were €37,146 per patient; for patients in the BSC
group, these were €3678 before discounting. The main
cost drivers were drug costs, costs of hospitalizations,
and additional chemotherapy.
The resulting discounted incremental cost-effectiveness
ratios (ICERs) amounted to €114,907 per LY gained and
€133,527 per QALY. The undiscounted results are pre-
sented in Table 4.
Probabilistic sensitivity analysis
When uncertainty was addressed in the PSA, the mean
discounted ICER was €133,812/QALY (95% CI,
€92,521-€184,072; Table 3). The associated cost-
effectiveness acceptability curve for the discounted cost per
QALY showed that at a value of €100,000/QALY, the
Table 1 Main unit costs
Unit description Cost, 2013 €
Oncology inpatient day 518
Intensive care day 2201
Oncology daycare visit 177
Oncology outpatient visit 104
Consultation by phone 15
Laboratory service by day 45
Emergency room visit 184
X-ray 52
Computed tomography scan 223
Magnetic resonance imaging 258
Radionuclear scan 193
Positron emission tomography scan 1485
Ultrasound 79
Colonoscopy 438
Port-A-Cath insertion 399
Radiotherapy (fraction) 97
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probability of cetuximab being a cost-effective strategy was
approximately 10%; at a threshold value of €150,000/QALY,
the probability was approximately 80% (Fig. 3). The scatter
plot of ICERs from the PSA is shown in Fig. 4. This figure
shows that in all PSA runs, cetuximab resulted in QALY
gains, however, at the same time, also in considerable
additional costs. The mean undiscounted ICER of the PSA
was €138,296 and yielded a range for the ICER of €92,521
to €184,072.
Discussion
To our knowledge, this study is the first of its kind to
calculate a real-world ICER for cetuximab in this setting.
The results led to an ICER of €133,527/QALY (95% CI,
€92,521-€184,072/QALY).
Our study has some limitations. First, clinical re-
cords did not contain sufficient information to deter-
mine PFS in the BSC group and, furthermore, no
quality-of-life data were available in the medical re-
cords. To overcome this shortcoming, data from ran-
domized controlled trials (RCTs) were used to
populate the model in cases in which real-world data
were lacking. RCT data were extrapolated and com-
bined with real-world data to populate the BSC arm
of the model, and we also applied quality-of-life data
derived from the same RCT [12]. In the RCTs and in
real-world data, treatment with cetuximab compared
with BSC was associated with almost a doubling of
the median OS and PFS among patients with KRAS
wt tumors.
In an RCT, patients are treated according to a prede-
fined protocol and have more active follow-up than pa-
tients treated under real-world conditions. Additionally,
RCTs often apply stricter inclusion and exclusion criteria
(e.g., patients with good performance status and few co-
morbidities), whereas in the real world, older patients
with a multitude of comorbidities and poorer condition
are also eligible [13]. In the RCTs, more patients had
colon and/or rectum cancer. In the real-world data,
there were relatively more rectosigmoid cancers. Con-
cerning the performance status, the availability of re-
corded data was too limited to draw a conclusion about
differences between the states of patients. Further, the
RCT patients in general received more adjuvant
Fig. 1 Model structure. mCRC, metastatic colorectal cancer
Table 2 Distributions used per parameter in the probabilistic
sensitivity analysis
Parameter Type of distribution Source
Transition probabilities Weibull distribution Real-world data and RCT
Costs γ distribution Real-world data
Utilities β distribution RCT
RCT randomized controlled trial
Table 3 Baseline characteristics of patients in outcomes study
Patients previously
treated with two
treatment lines
Cetuximab
group (n = 23)
BSC group
(n = 35)
P values
Male 60% 65% NS (p =
0.16)
Age, median (years) 64 60 p < 0.05
PS 0 26% 6% p < 0.05
1 17% 11%
2 9% 3%
3 – –
4 4% –
Unknown 43% 80%
Location Colon 48% 54% NS (p = 0.9)
Rectum 35% 31%
Rectosigmoid 13% 9%
Unknown 4% 6%
Charlson
Indexa
6 35% 63% NS (p = 0.1)
7 35% 17%
8 17% 11%
9 – 6%
10 9% –
Unknown 4% 3%
Mean total treatment
duration (days)
398 264 p < 0.05
Mean treatment
duration prior to
BSC or cetuximab (days)
268 264 NS (p = 0.9)
BSC best supportive care, NS not significant, PS performance status
aSeverity as scored with the Charlson Index; the presence of mCRC leads to an
automatic score of 6 as baseline
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treatments than the real-world patients did. As a result,
treatments given may have been less intensive and the
outcome of these treatments may have been worse than
those seen in RCTs [13].
Our study design did not allow for randomization of
patients. However, by matching patients from the con-
trol group to patients in the cetuximab group, we
corrected for differences between the two groups at
baseline. This way, known possible confounders were
corrected for. However, whether eligible patients may re-
ceive cetuximab in daily practice depends on physician
and patient choice; the rationale is not always provided
in the medical record. As a result, we could not directly
correct for these possible confounders.
Fig. 2 Kaplan-Meier estimates of survival for patients treated in the third line with cetuximab or BSC. BSC, best supportive care
Table 4 Results of model analysis (deterministic and probabilistic sensitivity analysis)
LY (95% CI) QALY (95% CI) Cost, € (95% CI)
Deterministic analysis (undiscounted)
Cetuximab + BSC 0.61 0.48 37,146
BSC 0.32 0.24 3678
Incremental 0.29 0.25 33,468
ICER 115,690 134,495
Deterministic analysis (discounted)
Cetuximab + BSC 0.61 0.48 36,637
BSC 0.32 0.23 3648
Incremental 0.29 0.25 32,989
ICER 114,907 133,527
PSA (undiscounted)
Cetuximab + BSC 0.61 (0.57–0.64) 0.48 (0.45–0.51) 36,915 (26,773–48,716)
BSC 0.32 (0.30–0.34) 0.24 (0.22–0.25) 3639 (2520–4982)
Incremental 0.29 (0.25–0.33) 0.25 (0.21–0.28) 33,276 (22,720–45,027)
ICER 116,030 (80,417–158,009) 134,777 (92,521–184,072)
PSA (discounted)
Cetuximab + BSC 0.61 (057–0.64) 0.48 (0.45–0.51) 36,410 (26,407–48,053)
BSC 0.32 (0.30–0.34) 0.24 (0.22–0.25) 3609 (2498–4942)
Incremental 0.29 (0.24–0.33) 0.25 (0.21–0.28) 32,801 (22,394–44,397)
ICER 115,248 (79,861–156,946) 133,812 (92,521–184,072)
BSC best supportive care, ICER incremental cost-effectiveness ratio, LY life-year, PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year
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Further, we assumed similarity of the effect ratio be-
tween the clinical trial and routine daily practice. The
literature has shown that when patient characteristics
were similar between RCT data and real-world data, as-
suming similarity in effect size yielded a valid approxi-
mation of relative effectiveness outcomes [14]. In our
study, these differences, were marginal and tested in
the PSA.
Cost data collection was conducted from a hospital
perspective rather than a societal perspective [11]. A
hospital perspective was chosen for this study because a
societal perspective was not feasible. Societal costs were
therefore not collected; however, due to the patients’ ex-
tended survival, the main sources of nonmedical costs in
the Netherlands are often productivity loss or additional
medical expenses unrelated to the condition under
Fig. 3 Cost-effectiveness acceptability curve of the discounted model analysis. BSC, best supportive care; ICER, incremental cost-effectiveness
ratio; QALY, quality-adjusted life-year
Fig. 4 Scatter plot of ICERs from the undiscounted probabilistic sensitivity analysis. PSA, probabilistic sensitivity analysis; QALY, quality-adjusted
life-year; WTP, willingness to pay
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study. The population in this study had a mean age of
63 years, while the mean age of retirement in the
Netherlands in 2009 was < 63 years [15]. Productivity
losses, or potential gains, will therefore be minimal in
this population. Additionally, because the survival of pa-
tients with mCRC often does not extend beyond 2 years,
even with optimal treatment, it is unlikely that medical
expenses unrelated to the primary condition would yield
a large difference between the treated and BSC groups
in this study. However, travel costs are a type of cost that
may differ between these two groups as patients treated
with cetuximab require weekly hospital visits to receive
treatment, whereas patients receiving only BSC will visit
less regularly. The differences in costs may be limited
because cetuximab is a treatment that can be given at
nearly any hospital, and the average distance to a hos-
pital in the Netherlands is only 7 km [16].
Additionally, home care provided to a patient by a
spouse, family member, or friend may lead to loss of
productivity for the caregiver, and both longer sur-
vival and side effects in patients receiving cetuximab
may result in more loss of productivity for their care-
givers than would occur for patients receiving BSC
only. We did not estimate the impact of these costs
on the ICER.
For the cost analysis, different sources were used.
Some limitations may be introduced by drawing data
from different sources; however, the rationale for using
different sources is inherent to the study design. Some
data could not be obtained from hospitals, such as the
resource use of BSC. However, Dutch guidelines provide
a valid and reliable framework for such resource use and
associated costs. Furthermore, the impact of the differ-
ent costs has been studied by conducting a PSA.
Scientific articles on the cost utility of cetuximab
monotherapy are scarce [17]. Hoyle et al. [18] reported
an ICER of €127,300/QALY for cetuximab compared
with BSC based on an indirect treatment comparison. In
that study, utility values were adapted based on general
population values, and resource use was partially based
on patients treated for breast cancer.
Tappenden et al. [19] performed a threshold analysis
from a UK National Health Service perspective. The
conclusion of this analysis was that it was unlikely that
an ICER of < €40,200/QALY could be achieved with
cetuximab, even when a rule was applied that would
mandate treatment to be stopped if no effect was ob-
servable after 6 weeks. Mittmann et al. [20] calculated
the cost effectiveness of cetuximab treatment in
Canada and reported an ICER for cetuximab of
€209,729/QALY compared with BSC, substantially
higher than the result of €134,777/QALY found in this
study. This difference may be due to resource use in
the analysis by Mittmann et al. being determined
through trial data rather than daily practice. Addition-
ally, the Mittmann publication references a higher
per-mg cost of cetuximab than the drug cost used in
our calculations.
Publications on the cost-effectiveness of panitumu-
mab, a biologic with a similar marketing license, are
scarce as well [17]. Hoyle et al. [18] reported an ICER
for panitumumab in the United Kingdom of €250,580/
QALY compared with BSC. The only other report on
panitumumab cost-effectiveness was published only as
an abstract by Graham et al. [21]. The ICERs reported
were for the comparison of panitumumab plus BSC vs.
BSC alone as third-line treatment of patients with KRAS
(exon 2) wt mCRC. The ICERs were €51,314/LY gained
and €59,440/QALY gained. These estimates were based
on RCT data only, and the analyses were performed in a
Dutch setting. Because the report is in abstract form
only, the information presented was limited [17].
An upper bound of €80,000/QALY has been suggested
for the Netherlands for the most severe illnesses [22].
Recently, however, there has been discussion on whether
drugs used during the last stages of illness (end-of-life
products) should be held to a different standard, as is
the case in the United Kingdom [23, 24]. If so, a higher
threshold might be more appropriate for such drugs.
Additionally, the panitumumab indication was changed
based on an analysis published by Douillard et al. [25],
whereas the cetuximab indication was changed based on
the re-analysis of the OPUS and CRYSTAL studies with re-
gard to NRAS and KRAS exons 3 and 4 mutations [26, 27].
Conclusions
Our research showed an incremental effectiveness for use
of cetuximab in third-line treatment of KRAS (exon 2) wt
mCRC of 0.25 QALYs over BSC in Dutch daily practice.
The resulting discounted, deterministic ICERs were
€114,907/LY and €133,527/QALY. Drug costs were identi-
fied as the main cost driver.
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